Skip to content
Pharmacy benefit managers (PBMs) create unnecessary barriers between patients and the medicine they need, experts explained during a Nov. 25 virtual “Patient Advocacy Coffee […]
Harms of PBMs explained in BIO Patient Advocacy Coffee Chat Read More »
As biotech breakthroughs enable remarkable advances in treatment and prevention of disease, we need similar levels of innovation in access, so patients benefit from
BIO CEO John F. Crowley calls for innovation in access at Milken Health Summit Read More »
Biotech firms weighing an initial public offering (IPO) must consider timing, interest in their product, the macro environment—and whether they really need all the
BIO Investor Forum panel breaks down when, what, and why of IPOs Read More »
The tide has been rising in biotech investment in 2024—though it has not lifted all boats equally. While the volume of investment improved in
BIO Investor Forum opens with encouraging news on financing Read More »
Colorado’s efforts to impose price controls on prescription drugs are preempted by federal law, according to a legal brief by the Biotechnology Innovation Organization
Colorado price-setting board conflicts with federal law, BIO tells court Read More »
Food and Drug Administration (FDA) inaction on patents for drug delivery devices has been troubling drug manufacturers for 20 years, and the situation is
Sen. Cassidy calls on FDA to act, not abdicate, on drug device patents Read More »
As Claudia Sheinbaum became Mexico’s president on Oct. 1, a bipartisan letter from 21 American Congress members called on U.S. officials to resolve the
As Mexico changes presidents, House members urge action on corn ban Read More »
During a busy week in Congress, House legislation to support drug development for pediatric rare diseases moved forward with bipartisan support, and a Senate
Capitol Hill update: House advances PPRV reauthorization, Senate reviews IRA Read More »
Members of Congress discussed legislation to block proposed federal rules that would regulate growth of genetically engineered crops on wildlife refuges during a Sept.
House members seek to block new wildlife refuge rules regarding GE crops Read More »
Market concentration allows pharmacy benefit managers (PBMs) to siphon off funds from our health care system while increasing costs to patients and reducing access
House hearing delves into antitrust problems of PBMs Read More »
